產品屬性：
產品名稱 | Naftidrofuryl oxalate |
規格 | 10mM*1 mL in DMSO、100mg |
貨號 | EY-01Y17642 |
Cas No.: 6/4/3200
別名: N/A
化學名: N/A
分子式: C26H35NO7
分子量: 473.56
溶解度: DMSO: ≥ 100 mg/mL (211.17 mM); H2O: 100 mg/mL (211.17 mM)
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
Naftidrofuryl oxalate (Nafronyl oxalate salt) is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.Naftidrofuryl oxalate (Nafronyl oxalate salt) may be effective for relieving the pain of muscle cramps[1].Naftidrofuryl oxalate (Nafronyl oxalate salt) is the only vasoactive drug for peripheral arterial disease (PAD) which is likely to be cost-effective[2].Naftidrofuryl oxalate (Nafronyl oxalate salt) is ranked first for both maximum walking distance (MWD) and pain-free walking distance (PFWD) (probability of 0.947 and 0.987, respectively, of being the best treatment) followed by cilostazol and pentoxifylline. Naftidrofuryl oxalate (Nafronyl oxalate salt) is effective treatments for claudication, Naftidrofuryl oxalate is likely to be the most effective, with minimal serious adverse events[3].[1]. Naftidrofuryl
[2]. Meng Y, et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology. 2014 Mar;65(3):190-197.
[3]. Stevens JW, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012 Dec;99(12):1630-1638.
特別提醒公司產品僅供科研使用
